What is Citius Oncology, Inc.'s stock issuance proceeds?

Citius Oncology, Inc. (CTOR) reported stock issuance proceeds of $15.13M in Q4 2025.

What does stock issuance proceeds mean?

Captures the total cash inflows received from the sale of equity shares to investors. This metric highlights the company's ability to raise capital from public or private markets to fund operations, research, or strategic initiatives.

Citius Oncology, Inc. CTOR Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Balance sheet

See full

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Cash flow

See full

Operating cash flow-$3.8M-179%

Valuation

See full

Market cap$60.45M-74.7%

Returns & leverage

See full

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Citius Oncology, Inc.'s stock issuance proceeds?: Citius Oncology, Inc. (CTOR) reported stock issuance proceeds of $15.13M in Q4 2025.
What does stock issuance proceeds mean?: Captures the total cash inflows received from the sale of equity shares to investors. This metric highlights the company's ability to raise capital from public or private markets to fund operations, research, or strategic initiatives.